Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. Issue 11 (November 2015)

• Record Type: Journal Article
• Authors: Facciorusso, Antonio; Del Prete, Valentina; Crucinio, Nicola; Muscatiello, Nicola; Carr, Brian I; Di Leo, Alfredo; Barone, Michele
• Is Part Of: Journal of gastroenterology and hepatology. Volume 30:Issue 11(2015:Nov.)
• Page Start: 1643
• Page End: 1650
• Publication Date: 2015-11
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12988
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12988-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. The aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation.</p> </sec> <sec id="jgh12988-sec-0002" sec-type="section"> <title>Methods</title> <p>Data on 153 patients were reviewed. The study population was classified into three groups: 73 (47.8%) patients who received neither angiotensin‐converting enzyme inhibitors nor sartans (group 1), 49 (32%) patients treated with angiotensin‐converting enzyme inhibitors (group 2), and 31 (20.2%) patients treated with sartans (group 3). Survival outcomes were analysed by means of Kaplan–Meier analysis and compared with log–rank test.</p> </sec> <sec id="jgh12988-sec-0003" sec-type="section"> <title>Results</title> <p>In the whole study population, 85.6% of patients were in Child–Pugh A class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40) and alpha fetoprotein was 25 (1.1–2100) UI/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (95% confidence interval: 31–58) in group 1, 72 months (49–89) in group 2, and 84 months (58–92) in group 3 (<italic>P</italic> = 0.02). Median time to recurrence was 26 (15–42), 44 (33–72), and 69 (44–74) months in the three groups, respectively (<italic>P</italic> = 0.02). Sartan therapy was a significant predictor of longer overall survival and delayed time to recurrence on multivariate analysis.</p> </sec> <sec id="jgh12988-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients.</p> </sec> </abstract>